US3701772A - Production of nucleotide anhydrides - Google Patents
Production of nucleotide anhydrides Download PDFInfo
- Publication number
- US3701772A US3701772A US42579A US3701772DA US3701772A US 3701772 A US3701772 A US 3701772A US 42579 A US42579 A US 42579A US 3701772D A US3701772D A US 3701772DA US 3701772 A US3701772 A US 3701772A
- Authority
- US
- United States
- Prior art keywords
- tri
- acid
- reaction
- phosphate
- mono
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002773 nucleotide Substances 0.000 title abstract description 30
- -1 nucleotide anhydrides Chemical class 0.000 title description 30
- 238000004519 manufacturing process Methods 0.000 title description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract description 54
- 238000000034 method Methods 0.000 abstract description 29
- 239000002253 acid Substances 0.000 abstract description 28
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract description 27
- BHIIGRBMZRSDRI-UHFFFAOYSA-N [chloro(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(Cl)OC1=CC=CC=C1 BHIIGRBMZRSDRI-UHFFFAOYSA-N 0.000 abstract description 21
- 230000008569 process Effects 0.000 abstract description 20
- 239000002904 solvent Substances 0.000 abstract description 18
- UQSHIDHNLKIYGN-UHFFFAOYSA-N diphenoxyphosphoryl diphenyl phosphate Chemical compound C=1C=CC=CC=1OP(OP(=O)(OC=1C=CC=CC=1)OC=1C=CC=CC=1)(=O)OC1=CC=CC=C1 UQSHIDHNLKIYGN-UHFFFAOYSA-N 0.000 abstract description 12
- 239000000463 material Substances 0.000 abstract description 12
- 150000003839 salts Chemical class 0.000 abstract description 10
- 150000003973 alkyl amines Chemical class 0.000 abstract description 8
- 150000008064 anhydrides Chemical class 0.000 abstract description 7
- 238000006243 chemical reaction Methods 0.000 description 28
- 229910019142 PO4 Inorganic materials 0.000 description 18
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
- 239000010452 phosphate Substances 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- 125000005210 alkyl ammonium group Chemical group 0.000 description 11
- 235000011180 diphosphates Nutrition 0.000 description 9
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- ASMQGLCHMVWBQR-UHFFFAOYSA-M diphenyl phosphate Chemical compound C=1C=CC=CC=1OP(=O)([O-])OC1=CC=CC=C1 ASMQGLCHMVWBQR-UHFFFAOYSA-M 0.000 description 8
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 7
- 238000005349 anion exchange Methods 0.000 description 7
- XTAZYLNFDRKIHJ-UHFFFAOYSA-N n,n-dioctyloctan-1-amine Chemical compound CCCCCCCCN(CCCCCCCC)CCCCCCCC XTAZYLNFDRKIHJ-UHFFFAOYSA-N 0.000 description 7
- 235000021317 phosphate Nutrition 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- HJHUXWBTVVFLQI-UHFFFAOYSA-N tributyl(methyl)azanium Chemical compound CCCC[N+](C)(CCCC)CCCC HJHUXWBTVVFLQI-UHFFFAOYSA-N 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- VWWQXMAJTJZDQX-UHFFFAOYSA-N Flavine adenine dinucleotide Natural products C1=NC2=C(N)N=CN=C2N1C(C(O)C1O)OC1COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UHFFFAOYSA-N 0.000 description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- 239000004305 biphenyl Substances 0.000 description 6
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 6
- IMFACGCPASFAPR-UHFFFAOYSA-O tributylazanium Chemical compound CCCC[NH+](CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-O 0.000 description 6
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- WFPZSXYXPSUOPY-ROYWQJLOSA-N ADP alpha-D-glucoside Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O WFPZSXYXPSUOPY-ROYWQJLOSA-N 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- WVIMUEUQJFPNDK-PEBGCTIMSA-N CDP-ethanolamine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCCN)O[C@H]1N1C(=O)N=C(N)C=C1 WVIMUEUQJFPNDK-PEBGCTIMSA-N 0.000 description 4
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 4
- HSCJRCZFDFQWRP-JZMIEXBBSA-N UDP-alpha-D-glucose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-JZMIEXBBSA-N 0.000 description 4
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000007810 chemical reaction solvent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- 239000001226 triphosphate Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- HXXFSFRBOHSIMQ-UHFFFAOYSA-N [3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dihydrogen phosphate Chemical compound OCC1OC(OP(O)(O)=O)C(O)C(O)C1O HXXFSFRBOHSIMQ-UHFFFAOYSA-N 0.000 description 3
- 239000003957 anion exchange resin Substances 0.000 description 3
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- QRGLCGLOQVQVCS-BCYSCTGWSA-K trisodium;[[[(2r,4s,5r)-3,4-dihydroxy-5-(6-oxo-3h-purin-9-yl)oxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl] hydrogen phosphate Chemical compound [Na+].[Na+].[Na+].O[C@H]1C(O)[C@@H](COP([O-])(=O)OP([O-])(=O)OP(O)([O-])=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 QRGLCGLOQVQVCS-BCYSCTGWSA-K 0.000 description 3
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 3
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 2
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- ZWIADYZPOWUWEW-XVFCMESISA-N CDP Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O1 ZWIADYZPOWUWEW-XVFCMESISA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 2
- CJUMAFVKTCBCJK-UHFFFAOYSA-N N-benzyloxycarbonylglycine Chemical compound OC(=O)CNC(=O)OCC1=CC=CC=C1 CJUMAFVKTCBCJK-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940113088 dimethylacetamide Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- OJVWCPKLFCTIPB-UHFFFAOYSA-N n,n-dibutylbutan-1-amine;phosphoric acid Chemical compound OP(O)([O-])=O.CCCC[NH+](CCCC)CCCC OJVWCPKLFCTIPB-UHFFFAOYSA-N 0.000 description 2
- WLRJJCBQEQTZMV-UHFFFAOYSA-N n,n-dibutylbutan-1-amine;sulfuric acid Chemical compound [O-]S([O-])(=O)=O.CCCC[NH+](CCCC)CCCC.CCCC[NH+](CCCC)CCCC WLRJJCBQEQTZMV-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- WRMXOVHLRUVREB-UHFFFAOYSA-N phosphono phosphate;tributylazanium Chemical compound OP(O)(=O)OP([O-])([O-])=O.CCCC[NH+](CCCC)CCCC.CCCC[NH+](CCCC)CCCC WRMXOVHLRUVREB-UHFFFAOYSA-N 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003222 pyridines Chemical class 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- GQNRBTVYHRLCIQ-HEIFUQTGSA-N (2S,3R,4S,5R)-3,4-dihydroxy-5-methyl-2-(6-oxo-1H-purin-9-yl)oxolane-2-carboxylic acid Chemical compound [C@]1([C@H](O)[C@H](O)[C@@H](C)O1)(N1C=NC=2C(O)=NC=NC12)C(=O)O GQNRBTVYHRLCIQ-HEIFUQTGSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- LTFMZDNNPPEQNG-KVQBGUIXSA-N 2'-deoxyguanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 LTFMZDNNPPEQNG-KVQBGUIXSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- RZZPDXZPRHQOCG-OJAKKHQRSA-M CDP-choline(1-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-M 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- ZWIADYZPOWUWEW-UHFFFAOYSA-N Cytidine 5'-diphosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(=O)OP(O)(O)=O)O1 ZWIADYZPOWUWEW-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- HAEJPQIATWHALX-KQYNXXCUSA-J ITP(4-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)O[C@H]1N1C(N=CNC2=O)=C2N=C1 HAEJPQIATWHALX-KQYNXXCUSA-J 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 241000692885 Nymphalis antiopa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- RZCIEJXAILMSQK-JXOAFFINSA-N TTP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 RZCIEJXAILMSQK-JXOAFFINSA-N 0.000 description 1
- 231100000579 Toxinosis Toxicity 0.000 description 1
- 102000057144 Uridine Diphosphate Glucose Dehydrogenase Human genes 0.000 description 1
- 108010054269 Uridine Diphosphate Glucose Dehydrogenase Proteins 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- DJJUUYLZKQCNDW-WAMDDSRMSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3s,4r,5r)-3,4,5,6-tetrahydroxy-1-oxohexan-2-yl] hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO)[C@@H](O)[C@H]1O DJJUUYLZKQCNDW-WAMDDSRMSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- HXXFSFRBOHSIMQ-VFUOTHLCSA-N alpha-D-glucose 1-phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HXXFSFRBOHSIMQ-VFUOTHLCSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- ITVPBBDAZKBMRP-UHFFFAOYSA-N chloro-dioxido-oxo-$l^{5}-phosphane;hydron Chemical compound OP(O)(Cl)=O ITVPBBDAZKBMRP-UHFFFAOYSA-N 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 1
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- SBNKFTQSBPKMBZ-UHFFFAOYSA-N ethenzamide Chemical compound CCOC1=CC=CC=C1C(N)=O SBNKFTQSBPKMBZ-UHFFFAOYSA-N 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- 229950010772 glucose-1-phosphate Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- ZFIUCZXOGNIMCP-UHFFFAOYSA-M methyl(trioctyl)azanium;hydroxide Chemical compound [OH-].CCCCCCCC[N+](C)(CCCCCCCC)CCCCCCCC ZFIUCZXOGNIMCP-UHFFFAOYSA-M 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- IOQPZZOEVPZRBK-UHFFFAOYSA-O octylazanium Chemical compound CCCCCCCC[NH3+] IOQPZZOEVPZRBK-UHFFFAOYSA-O 0.000 description 1
- 238000004816 paper chromatography Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- CMPQUABWPXYYSH-UHFFFAOYSA-N phenyl phosphate Chemical compound OP(O)(=O)OC1=CC=CC=C1 CMPQUABWPXYYSH-UHFFFAOYSA-N 0.000 description 1
- XENHFSZRMFXQBS-UHFFFAOYSA-N phosphoric acid;pyridine-3-carboxamide Chemical compound OP(O)(O)=O.NC(=O)C1=CC=CN=C1 XENHFSZRMFXQBS-UHFFFAOYSA-N 0.000 description 1
- 229950004354 phosphorylcholine Drugs 0.000 description 1
- PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000008359 toxicosis Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- QVOFCQBZXGLNAA-UHFFFAOYSA-M tributyl(methyl)azanium;hydroxide Chemical compound [OH-].CCCC[N+](C)(CCCC)CCCC QVOFCQBZXGLNAA-UHFFFAOYSA-M 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- JENUKVZGXGULDX-LLWADOMFSA-K trisodium;[[(2r,3s,4r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] phosphate Chemical compound [Na+].[Na+].[Na+].O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP([O-])(=O)OP([O-])([O-])=O)O1 JENUKVZGXGULDX-LLWADOMFSA-K 0.000 description 1
- DJJCXFVJDGTHFX-XVFCMESISA-L uridine 5'-monophosphate(2-) Chemical compound O1[C@H](COP([O-])([O-])=O)[C@@H](O)[C@@H](O)[C@@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-L 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/02—Phosphorylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Definitions
- Nucleotide anhydrides can be synthesized, in each case, by a single-step process by causing a nucleoside-S'-monophosphate and diphenyl phosphorochloridate or tetraphenyl pyrophosphate to react in a suitable solvent and in the presence of an alkylamine and then adding to the resulting process materials alkylammoniurn salt of an acid dissolved in pyridine or one of its derivatives.
- This invention relates generally to nucleotide anhydrides and production thereof and more particularly to a new and advanced process for producing nucleotide anhydrides by a one-step synthesis in a short time and in an economical manner.
- nucleotide anhydride is herein used to designate an anhydride of nucleoside-5'-monophosphate and an acid whose acidity is weaker than diphenylphosphate.
- the anhydrides can be represented by the following general formula and consist of the compounds indicated in Table 1.
- nucleotide anhydrides are very important substances for the metabolism within living organisms.
- CDP-choline is effective for treatment of external head injuries, coma due to external injury 3,701,772 Patented Oct. 31, 1972 to the brain, etc.
- Trisodium inosine-5'-triphosphate (ITP-Na and trisodium thymidine-S'-triphosphate (TIP-Na are present within muscles and are valuable reagents for research on metabolism within living organisms.
- Adenosine triphosphate (ATP) is used for the circulation, particularly peripheral vascular disturbances, edema, beri-beri, and muscular fatigue and for the treatment of myositis (myitis, sarcitis), myasthenia, rheumatosis, arthritis, neuralgia, and other similar ailments.
- Flavine adenine dinucleotide is used as a medicine in the treatment of hepatic disturbances, trophopathy in pregnant women and lactating (breast-feeding) women, and toxicosis (toxinosis, toxipathy) such as alcohol damage and nicotinism.
- trophopathy in pregnant women and lactating (breast-feeding) women
- toxicosis toxinosis, toxipathy
- UDPG-Na disodium uridine-S'-diphosphoglucose
- CDP-ethanolamine can be used as one kind of nucleotide coenzyme.
- uridylyl sulfate, adenosine-S-2,4-dinitrophenyl phosphate, adenyl-5'-yl carbobenzy oxyglycine, and other nucleotide anhydrides are highly promising for future development and application as medicines and biochemical reagents.
- the anion-exchange method comprises the following two steps.
- the first step is reaction of a nucleoside- 5'-monophosphate with tetraphenyl pyrophosphate or diphenyl phosphorochloridate in the presence of a tertiary base in dioxane or a mixture of dioxane and dimethyl formamide.
- the reaction product is P -nucleoside-5-P -diphenyl pyrophosphate.
- the second step is reaction of purified P -nucleoside-5'-P -diphenyl pyrophosphate with an acid (whose acidity is weaker than diphenyl phosphate) to produce a nucleotide anhydride.
- the second reaction is based on the transition elfect of pyridine.
- Various nucleoside-S-monophosphates and acids can be combined arbitrarily by the anion exchange method to prepare various nucleotide anhydrides.
- the purification of the intermediate product obtained by the first reaction is accomplished by concentrating the reaction mixture under reduced pressure to remove the solvent, adding ethyl ether to the resulting residue to precipitate the compound, letting the process material stand at 0 C. for 30 to 60 minutes, and removing the ether by decantation.
- this intermediate material is unstable when exposed to moisture and heat, it is necessary to carry out the concentration under an anhydrous condition, at a low temperature, and in a high vacuum.
- an extremely large quantity of ethyl ether is required for precipitation, giving rise to great danger for a large scale operation.
- the method is industrially disadvantageous.
- in the process for isolation of the intermediate material its significant loss is unavoidable.
- the above described known method requires two stages of reaction, and the operation for isolating the intermediate material, moreover, is complicated and requires a long time and complicated production equipment. Furthermore, a large quantity of the solvent is necessary, and a considerable amount of the intermediate material is lost.
- nucleotide anhydride can be synthesized in a single operation by causing a nucleoside-'- monophosphate and diphenyl phosphochloridate or tetraphenyl pyrophosphate to react in a suitable solvent and in the presence of an amine and then adding thereto an acid which .is weaker than diphenyl phosphate dissolved in pyridine or one of its derivatives.
- a process for synthesizing nucleotide anhydrides wherein diphenyl phosphorochloridate or tetraphenyl pyrophosphate is added to an alkyl-ammonium saltof a nucleoside-S'-monophosphate in dioxane, N,N- dimethylformamide or N,N-dirnethylac'etamide and in the presence of an alkylamine, and, to the resulting process materials, a solution in pyridine of an alkalammonium salt of an acid to be condensed with the 5-phosphate part of the desired nucleotide.
- a nucleoside-S'-monophosphate is generally used in the form of an alkylammonium salt in order to facilitate dissolution thereof in a reaction solvent.
- a salt of a trialkylamine or quarternary ammonium hydroxide for example, tri-n-buthylamine, tri-n-octylamine, methyl-trin-butylammonium hydroxide, or methyl-tri-n-octylammonium hydroxide.
- the mono (alkylarnmonium) salt and the di alkylammonium) salt may be obtained.
- the mono (alkylammonium) salt is principally used because of its reactivity.
- nucleotides can be employed as one of starting materials:
- Natural nucleotides such as 5'-cytidylic acid, 5'-deoxyadenylic acid, 5'-deoxyinosinic acid, 5'-deoxyguanylic acid, 5'-deoxycytidylic acid, 5'-thymidylic acid, and adenosine (2,3'-cyclic phosphate) 5'-phosphate and unnaturalnucleotides such as 2-methyl-thio-5-inosinic acid etc.
- reaction solvent whichv dissolves alkylammonium. salts of nuc1eoside-5'-phosphate and does not inhibit the reaction
- reaction solvents we have found to be suitable are N,N-dimethyl-.formamide, N,N-dimethylacetamide, and dioxane. While the minimum quantity of the solvent to be used is 5 times (in moles) that of the nucleoside-5'- phosphate, a preferable range is from to 50 times (in moles).
- the above three solvents can be used not only alone, respectively, but also as a mixture of two or three thereof.
- tetrahydrofuran, n-hexane, benzene, toluene, ethyl acetate, acetone, or chloroform can be added to the solvent to an extent that the reaction is not inhibited.
- the limit to the quantity be added is 2 to 3 times by volume that of the reaction solvent, and equal volume or less is preferable.
- Diphenyl phosphorochloridate or tetraphenylpyrophosphate should be used so that its molar ratio to nucleoside- 5-phosphate is 1-2, preferentially 1-1.5.
- alkylamine which is added as a reaction stabilizer examples include trin-n-ethylarnine, tri-n-ethylamine, tri-noctylamine, N-methylpiperidine, and diethylaniline.
- the stabilizer should be employed in an amount more than 0.5 mole, preferentially 1.2-2 moles, per one molar of the nucleoside-5'-phosphate.
- nucleoside5-phosphate After the reaction of nucleoside5-phosphate with diphenyl phosphorochloridate or tetraphenylpyrophosphate, a desired acid dissolved in pyridine or its derivative is directly added to the reaction mixture, where the reaction forming nucleotide anhydride from the nucleoside- 5'-monophosphate and the acid can be observed.
- the added acid should be a weaker acid than diphenyl phosphate. An acid whose acidity is stronger than that of diphenyl phosphate failed to form an acid anhydride with nucleoside-5-phosphate.
- Examples of an acid weaker than diphenyl phosphate are: Anhydrous sulfuric acid, phosphates such as orthophosphate, pyrophosphate, and triphosphate; sugar phosphates such as glucose-l-phosphate, mannose-l-phosphate, and galactose-l-phosphate; carboxylic acids such as acetic acid, and propionic acid, carbobenzyloxy amines; peptides; phenols such as 2,4-dinitrophenol; nucleosides; and acid constitutents of coenzymes (for example, panthethin-4', 4'-bisphosphate, flavine monoculeotide, phenyl phosphate, choline phosphate, and nicotinamide phosphate).
- phosphates such as orthophosphate, pyrophosphate, and triphosphate
- sugar phosphates such as glucose-l-phosphate, mannose-l-phosphate, and galactose-l-phosphate
- the acid is ordinarily added in the form of a salt of an alkylamine as, for example, tri-n-butylamine or tri-n-octylamine.
- the acid should be used in an amount of more than one mole, preferentially 1-2 moles, per one molar of the nucleoside-5-phosphate.
- Substances Which dissolve in pyridine with difficulty such as flavine nucleotide, is dissolved in another solvent such as a formamide before mixing with pyridine.
- pyridine derivatives such as picoline, lutidine, and cholidine can also be used. 2-50 moles, particularly 5-30 moles, of pyridine or its derivative per 1 mole of the nucleotide gives a good yield.
- the reactions in the process according to the invention are generally completed in a relatively short time, although the time depends on the kind and quantity of the solvent used and the temperature.
- P -nucleoside-5'-P -diphenyl pyrophosphate is usually synthesized almost immediately after mixing nucleoside- 5-phosphate and diphenyl phosphorochloridate or tetraphenyl pyrophosphate under the conditions described previously. Therefore, the acid dissolved in pyridine or its derivative can be added to the reaction mixture almost immediately after mixing nucleoside5'-phosphate and diphenylphosphorochloridate or tetraphenyl pyrophosphate.
- the anion exchange reaction is completed in a few minutes to a few hours, in a high yield, with formation of only small amounts of by-products.
- the anion exchange reaction can also be carried out a few minutes to a few hours after mixing nucleoside-5'- phosphate and diphenyl phosphorochloridate or tetraphenyl pyrophate.
- nucleotide anhydride can be synthesized directly in one vessel containing a complicated solvent system where several materials are added successively. Furthermore, the synthesis of the nucleotide anhydride proceeds rapidly in a high yield, with formation of only small amounts of by-products.
- the inventors discovered this surprising fact for the first time.
- the present invention based on this new discovery, thus establishes an economical process for synthesizing nucleotide anhydrides which is a superior, as will be indicated hereinafter, to the known method mentioned hereinbefore.
- the nucleotide anhydrides produced by the process of the invention are purified by a combination of processes such as ion exchange resin column chromatography, and precipitation process with an organic solvent and/or other precipitants.
- the purified products were identified with respective nucleotide anhydrides by means of paper chromatography with several solvents, and physical, chemical and enzymatic analyses.
- Example 1 Trisodium cytidine-'-diphosphate (CDP a) To one mole of mono (methyl tri-in-butylammonium)- 5'-cytidylate, 1,500 mol. of N,N-dimethylacetamide was added, and then 250 ml. of diphenyl phosphorochloridate was added.
- CDP a Trisodium cytidine-'-diphosphate
- the mixture was agitated for 5 minutes to dissolve the materials.
- 500 ml. of tri-n-butylamine and 2 l. of dioxane were then added to the batch.
- reaction mixture was concentrated in vacuo, added with 7 l. of water, then extracted with one litre" of benzene.
- the water layer is diluted to 50 1., and applied to an anion exchange resin Duolite A101D (Cl type, 101.) column. Cytidine-5'-diphosphate was eluted from the column with 0.1 N hydrochloride, and crystallized as trisodium salt (387 grammes (g.) (11.0 percent moisture)). Yield 73.5 percent.
- Example 2 Trisodium inosine-5'-triphosphate (ITP Na To 200 millimoles of mono (tri-n-butylammoniurn) 5'-inosinate, 120 ml. of N,N-dimethyl acetamide and mixture of 250 millimoles of tetraphenylpyrophosphate, 100 ml. of tri-n-butylamine, and 600 ml. of dioxane were added successively.
- IPP Na To 200 millimoles of mono (tri-n-butylammoniurn) 5'-inosinate, 120 ml. of N,N-dimethyl acetamide and mixture of 250 millimoles of tetraphenylpyrophosphate, 100 ml. of tri-n-butylamine, and 600 ml. of dioxane were added successively.
- Example 4 Disodium uridine-5'-diphosphoglucose (UDPG Na l0 millimoles of mono (tri-n-butylammonium) 5-uridylate was dissolved in 5 ml. of N,N-dimethylformamine, and 5 m1. of dioxane, 6 ml. of tri-n-butylamine, and 2.3 ml. of diphenyl phosphorochloridate were added to the resulting solution.
- UDPG Na l0 millimoles of mono (tri-n-butylammonium) 5-uridylate was dissolved in 5 ml. of N,N-dimethylformamine, and 5 m1. of dioxane, 6 ml. of tri-n-butylamine, and 2.3 ml. of diphenyl phosphorochloridate were added to the resulting solution.
- Example 5 Adenosine-5-diphosphoglucose (ADPG) To one millimole of mono (methyl-tri-n-butylammonium) 5'-adenylate, 1 ml. of N,N-dimethy1 acetamide, 0.22 ml., of dephenyl phosphorochloridate 1 ml. of dioxane, and 0.5 ml. of tri-n-butylamine were added successively.
- ADPG AdPG
- Example 6 Flavine-adenine-dinucleotide (FAD) One millimole of mono (tri-n-octylammonium) 5'- adenylate was dissolved in 1 ml. of N,N-dimethyl acetamide, and to the resulting solution, 0.25 ml. of diphenyl phosphorochloridate 2 ml. of dioxane, and 0.5 ml. of trin-butylamine were added.
- Example 7 CDP-ethanolamine Two millimoles of mono (methyl tri n octylammonium) 5-cytidylate was dissolved in 2 ml. of N,N-dirnethyl formamide, and to resulting solution, 0.5 ml. of diphenyl phosphorochloridate, 1 ml. of tri-n-butylamine, and 15 ml. of dioxane were added, the resulting solution and then being mixed.
- Example 8 Ultraviolet sulfate 10 millimoles of mono (tri-n-octylammonium) 5'-uridylate was dissolved in 20 ml. of dioxane, and to the resulting solution, 2.5 ml. of diphenyl phosphorochloridate and 2.1 ml. of triethylamine were added.
- reaction uridylyl sulfate was synthe sized in a yield of 40 percent.
- Example 9 Adenosine-5'-2,4-dinitrophenyl-phosphate
- 2 ml. of N,N-dimethyl acetamide was added, and then 0.25 ml. of diphenyl phosphorochloridate and 0.6 ml. of tri-n-butylamine were added after allowing it to stand at room temperature for one hour, 2 ml. of pyridine containing a solution of 2 millimoles of 2,4- dinitrophenol was added to the mixture.
- Example 10 Adenyl-'-yl-carbobenzyl oxyglycine To 1 millimole of mono (tri-n-octylammonium) 5- adenylate, 2 m1. of N,N-dimethy1 acetamide was added, after. agitation a mixture of 0.25 ml. of diphenyl phosphorochloridate, 4 ml. of dioxane, and 0.5 ml. of tri-nbutylamine were added to the solution, which was then thoroughly agitated for dissolution.
- a one-stage process for producing a nucleotide anhydride which comprises adding a member selected from the group consisting of diphenyl phosphorochloridate and tetraphenyl pyrophosphate to an alkylammonium salt of a nucleoside-S'-monophosphate in a reaction solvent selected from the group consisting of dioxane, dimethylformamide, and dimethylacetamide and in the presence of an alkylamine and adding to the resulting mixture an alkylammonium salt of an acid dissolved in pyridine or one of its derivatives whereby said anhydride is produced in a single stage without isolation of an intermediate.
- said alkyl-ammonium salt of a nucleoside-S'-monophosphate is selected from mono (methyl-tri-n-butylammonium)-5'- cytidylate,
- alkyl-ammonium salt of an acid is selected from I mono (tri-n-butylammonium) phosphate,
- CD'P Na trisodium inosine-5'-triphosphate INP Na trisodium thymidine-S'-triphosphate
- TIP trisodium uridine 5' diphosphoglucose
- ADPG adenosine-5'-diphosphoglucose
- FAD fiavine-adenine-dinucleotide
- CDP-ethanolamine uridylyl sulfate, adenosine-S'-2,4-dinitrophenylphosphate, and adenyl- '-yl-carbobenzyl oxyglycine.
- nucleotide anhydride by the steps of reacting a nucleoside-5-monophosphate with a reagent selected from a member of the group consisting of tetraphenyl pyrophosphate and diphenyl phosphorochloridate in the presence of a tertiary base and in a solvent, isolating and purifying the resultant P -nucleoside-5'-P -dipheny1 pyrophosphate, and then reacting said P -nucleoside-5'-P -diphenyl pyrophosphate with an acid having a weaker acidity than diphenyl phosphate to produce said anhydride, the improvement which comprises carrying out said preparation in a single stage without isolation and purification of said P -nucleoside- 5'-P -diphenyl pyrophosphate by mixing an alkylammonium salt of said nucleoside-5'-monophosphate with said reagent in
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Saccharide Compounds (AREA)
Abstract
NUCLEOTIDE ANHYDRIDES CAN BE SYNTHESIZED, IN EACH CASE, BY A SINGLE-STEP PROCESS BY CAUSING A NUCLEOSIDE-5''-MONOPHOSPHATE AND DIPHENYL PHOSPHOROCHLORIDATE OR TETRAPHENYL PYROPHOSPHATE TO REACT IN A SUITABLE SOLVENT AND IN THE PRESENCE OF AN ALKYLAMINE AND THEN ADDING TO THE RESULTING PROCESS MATERIALS ALKYLAMMONIUM SALT OF AN ACID DISSOLVED IN PYRIDINE OR ONE OF ITS DERIVATIVES.
Description
United States Patent PRODUCTION OF NUCLEOTIDE ANHYDRIDES Kiminori Tamura, Manami Morozumi, Yutaka Noda, Morio Suzuki, and Hiroshi Yoshino, Choshi-shi, Japan, assignors to Yamasa Shoyu Kabushiki Kaisha, Araoi, Choshi-shi, Chiba-ken, Japan No Drawing. Filed June 1, 1970, Ser. No. 42,579 Claims priority, application Japan, June 12, 1969, 44/ 45,786 Int. Cl. C07d- 51/50 US. Cl. 260-211.5 R 4 Claims ABSTRACT OF THE DISCLOSURE Nucleotide anhydrides can be synthesized, in each case, by a single-step process by causing a nucleoside-S'-monophosphate and diphenyl phosphorochloridate or tetraphenyl pyrophosphate to react in a suitable solvent and in the presence of an alkylamine and then adding to the resulting process materials alkylammoniurn salt of an acid dissolved in pyridine or one of its derivatives.
BACKGROUND OF THE INVENTION This invention relates generally to nucleotide anhydrides and production thereof and more particularly to a new and advanced process for producing nucleotide anhydrides by a one-step synthesis in a short time and in an economical manner.
The term nucleotide anhydride is herein used to designate an anhydride of nucleoside-5'-monophosphate and an acid whose acidity is weaker than diphenylphosphate. The anhydrides can be represented by the following general formula and consist of the compounds indicated in Table 1.
These nucleotide anhydrides are very important substances for the metabolism within living organisms, and
pharmaceutical and biochemical demand thereof is recently increasing.
For example, CDP-choline is effective for treatment of external head injuries, coma due to external injury 3,701,772 Patented Oct. 31, 1972 to the brain, etc. Trisodium inosine-5'-triphosphate (ITP-Na and trisodium thymidine-S'-triphosphate (TIP-Na are present within muscles and are valuable reagents for research on metabolism within living organisms. Adenosine triphosphate (ATP) is used for the circulation, particularly peripheral vascular disturbances, edema, beri-beri, and muscular fatigue and for the treatment of myositis (myitis, sarcitis), myasthenia, rheumatosis, arthritis, neuralgia, and other similar ailments.
Flavine adenine dinucleotide (FAD) is used as a medicine in the treatment of hepatic disturbances, trophopathy in pregnant women and lactating (breast-feeding) women, and toxicosis (toxinosis, toxipathy) such as alcohol damage and nicotinism. In addition, disodium uridine-S'-diphosphoglucose (UDPG-Na is of physiological value, and CDP-ethanolamine can be used as one kind of nucleotide coenzyme. Moreover, uridylyl sulfate, adenosine-S-2,4-dinitrophenyl phosphate, adenyl-5'-yl carbobenzy oxyglycine, and other nucleotide anhydrides are highly promising for future development and application as medicines and biochemical reagents.
Among various methods so far established for synthesizing these nucleotide anhydrides, the anion-exchange method is considered at present to be the most advantageous. The anion-exchange method comprises the following two steps. The first step is reaction of a nucleoside- 5'-monophosphate with tetraphenyl pyrophosphate or diphenyl phosphorochloridate in the presence of a tertiary base in dioxane or a mixture of dioxane and dimethyl formamide.
The reaction product is P -nucleoside-5-P -diphenyl pyrophosphate. The second step is reaction of purified P -nucleoside-5'-P -diphenyl pyrophosphate with an acid (whose acidity is weaker than diphenyl phosphate) to produce a nucleotide anhydride. The second reaction is based on the transition elfect of pyridine. Various nucleoside-S-monophosphates and acids can be combined arbitrarily by the anion exchange method to prepare various nucleotide anhydrides.
In this case, the purification of the intermediate product obtained by the first reaction is accomplished by concentrating the reaction mixture under reduced pressure to remove the solvent, adding ethyl ether to the resulting residue to precipitate the compound, letting the process material stand at 0 C. for 30 to 60 minutes, and removing the ether by decantation. However, since this intermediate material is unstable when exposed to moisture and heat, it is necessary to carry out the concentration under an anhydrous condition, at a low temperature, and in a high vacuum. Furthermore, an extremely large quantity of ethyl ether is required for precipitation, giving rise to great danger for a large scale operation. Thus the method is industrially disadvantageous. Moreover, in the process for isolation of the intermediate material, its significant loss is unavoidable.
Furthermore, water or ethyl ether admixed with the intermediate material obtained by precipitation markedly inhibits the second reaction and lowers the yield. Accordingly, it is disadvantageously necessary to resort to a process step of dissolving the precipitate in dioxane and concentrating the resulting solution under reduced pressure to romve these liquids by azeotropy.
Thus, the above described known method requires two stages of reaction, and the operation for isolating the intermediate material, moreover, is complicated and requires a long time and complicated production equipment. Furthermore, a large quantity of the solvent is necessary, and a considerable amount of the intermediate material is lost.
On account of these difiiculties this method is not suitable for industrial production.
3 SUMMARY OF THE INVENTION It is an object of the present invention to overcome the above described difficulties by utilizing certain findings we have made and thereby to provide a new advanced process for synthesizing nucleotide anhydrides whereby the reaction can be completed in a short time in one step by a simple operation without isolation of the intermediate materials.
We have found that a nucleotide anhydride can be synthesized in a single operation by causing a nucleoside-'- monophosphate and diphenyl phosphochloridate or tetraphenyl pyrophosphate to react in a suitable solvent and in the presence of an amine and then adding thereto an acid which .is weaker than diphenyl phosphate dissolved in pyridine or one of its derivatives.
According to the present invention, briefly summarized, there is provided a process for synthesizing nucleotide anhydrides wherein diphenyl phosphorochloridate or tetraphenyl pyrophosphate is added to an alkyl-ammonium saltof a nucleoside-S'-monophosphate in dioxane, N,N- dimethylformamide or N,N-dirnethylac'etamide and in the presence of an alkylamine, and, to the resulting process materials, a solution in pyridine of an alkalammonium salt of an acid to be condensed with the 5-phosphate part of the desired nucleotide.
The nature, details, and utility of the invention will be more clearly apparent from the following detiled description beginning with general considerations and concluding with specificexamples of practice illustrating preferred embodiments of the invention.
DETAILED DESCRIPTION A nucleoside-S'-monophosphate is generally used in the form of an alkylammonium salt in order to facilitate dissolution thereof in a reaction solvent. Particularly in consideration of solubility in the solvent, use o-f a salt of a trialkylamine or quarternary ammonium hydroxide (for example, tri-n-buthylamine, tri-n-octylamine, methyl-trin-butylammonium hydroxide, or methyl-tri-n-octylammonium hydroxide) is recommended.
Depending on the molar ratio between the nucleoside- 5'-monophosphate and alkylamine base in condensation, the mono (alkylarnmonium) salt and the di alkylammonium) salt may be obtained.
While either kind of salt can be used, the mono (alkylammonium) salt is principally used because of its reactivity.
In the present invention, the following nucleotides can be employed as one of starting materials:
Natural nucleotides such as 5'-cytidylic acid, 5'-deoxyadenylic acid, 5'-deoxyinosinic acid, 5'-deoxyguanylic acid, 5'-deoxycytidylic acid, 5'-thymidylic acid, and adenosine (2,3'-cyclic phosphate) 5'-phosphate and unnaturalnucleotides such as 2-methyl-thio-5-inosinic acid etc.
Any (reaction) solvent, whichv dissolves alkylammonium. salts of nuc1eoside-5'-phosphate and does not inhibit the reaction, can be employed in this invention. Examples of. such reaction solvents We have found to be suitable are N,N-dimethyl-.formamide, N,N-dimethylacetamide, and dioxane. While the minimum quantity of the solvent to be used is 5 times (in moles) that of the nucleoside-5'- phosphate, a preferable range is from to 50 times (in moles).
The above three solvents can be used not only alone, respectively, but also as a mixture of two or three thereof. In addition, in order, to increase the solubility of the reaction reagents, tetrahydrofuran, n-hexane, benzene, toluene, ethyl acetate, acetone, or chloroform can be added to the solvent to an extent that the reaction is not inhibited. The limit to the quantity be added is 2 to 3 times by volume that of the reaction solvent, and equal volume or less is preferable.
Diphenyl phosphorochloridate or tetraphenylpyrophosphate should be used so that its molar ratio to nucleoside- 5-phosphate is 1-2, preferentially 1-1.5.
Examples of alkylamine which is added as a reaction stabilizer are trin-n-ethylarnine, tri-n-ethylamine, tri-noctylamine, N-methylpiperidine, and diethylaniline. The stabilizer should be employed in an amount more than 0.5 mole, preferentially 1.2-2 moles, per one molar of the nucleoside-5'-phosphate.
After the reaction of nucleoside5-phosphate with diphenyl phosphorochloridate or tetraphenylpyrophosphate, a desired acid dissolved in pyridine or its derivative is directly added to the reaction mixture, where the reaction forming nucleotide anhydride from the nucleoside- 5'-monophosphate and the acid can be observed. The added acid should be a weaker acid than diphenyl phosphate. An acid whose acidity is stronger than that of diphenyl phosphate failed to form an acid anhydride with nucleoside-5-phosphate.
Examples of an acid weaker than diphenyl phosphate are: Anhydrous sulfuric acid, phosphates such as orthophosphate, pyrophosphate, and triphosphate; sugar phosphates such as glucose-l-phosphate, mannose-l-phosphate, and galactose-l-phosphate; carboxylic acids such as acetic acid, and propionic acid, carbobenzyloxy amines; peptides; phenols such as 2,4-dinitrophenol; nucleosides; and acid constitutents of coenzymes (for example, panthethin-4', 4'-bisphosphate, flavine monoculeotide, phenyl phosphate, choline phosphate, and nicotinamide phosphate).
In consideration of the solubility of the acid in an organic solvent, the acid is ordinarily added in the form of a salt of an alkylamine as, for example, tri-n-butylamine or tri-n-octylamine.
The acid should be used in an amount of more than one mole, preferentially 1-2 moles, per one molar of the nucleoside-5-phosphate.
Substances Which dissolve in pyridine with difficulty, such as flavine nucleotide, is dissolved in another solvent such as a formamide before mixing with pyridine.
It is essential to add pyridine or its derivative together with the acid simultaneously: The reaction of the acid with P -nucleoside-5'-P -diphenyl' pyrophosphate is regarded as an anion exchange reaction Where diphenyl phosphate (a strong acid) moiety of the latter compound is replaced by the weak acid. Pyridine or its derivatives are essential for this anion exchange reaction.
This is the reason why pyridine or its derivative should be added together with the acid.
In addition to pyridine that is used satisfactorily, several pyridine derivatives such as picoline, lutidine, and cholidine can also be used. 2-50 moles, particularly 5-30 moles, of pyridine or its derivative per 1 mole of the nucleotide gives a good yield.
The reactions in the process according to the invention are generally completed in a relatively short time, although the time depends on the kind and quantity of the solvent used and the temperature.
P -nucleoside-5'-P -diphenyl pyrophosphate is usually synthesized almost immediately after mixing nucleoside- 5-phosphate and diphenyl phosphorochloridate or tetraphenyl pyrophosphate under the conditions described previously. Therefore, the acid dissolved in pyridine or its derivative can be added to the reaction mixture almost immediately after mixing nucleoside5'-phosphate and diphenylphosphorochloridate or tetraphenyl pyrophosphate. The anion exchange reaction is completed in a few minutes to a few hours, in a high yield, with formation of only small amounts of by-products.
The anion exchange reaction can also be carried out a few minutes to a few hours after mixing nucleoside-5'- phosphate and diphenyl phosphorochloridate or tetraphenyl pyrophate.
It is surprising that the nucleotide anhydride can be synthesized directly in one vessel containing a complicated solvent system where several materials are added successively. Furthermore, the synthesis of the nucleotide anhydride proceeds rapidly in a high yield, with formation of only small amounts of by-products.
The inventors discovered this surprising fact for the first time. The present invention, based on this new discovery, thus establishes an economical process for synthesizing nucleotide anhydrides which is a superior, as will be indicated hereinafter, to the known method mentioned hereinbefore.
The nucleotide anhydrides produced by the process of the invention are purified by a combination of processes such as ion exchange resin column chromatography, and precipitation process with an organic solvent and/or other precipitants. The purified products were identified with respective nucleotide anhydrides by means of paper chromatography with several solvents, and physical, chemical and enzymatic analyses.
In order to indicate still more fully the nature and utility of the present invention, the following specific examples of practice constituting preferred embodiments of the invention and results are set forth, it being understood that these examples are presented as illustrative only and that they are not intended to limit the scope of the invention.
Example 1.Trisodium cytidine-'-diphosphate (CDP a) To one mole of mono (methyl tri-in-butylammonium)- 5'-cytidylate, 1,500 mol. of N,N-dimethylacetamide was added, and then 250 ml. of diphenyl phosphorochloridate was added.
The mixture was agitated for 5 minutes to dissolve the materials. 500 ml. of tri-n-butylamine and 2 l. of dioxane were then added to the batch.
After stirring for 5 minutes, 2 l. of pyridine containing 2 moles of mono (tri-n-butylammonium) phosphate was added to the batch.
After agitation, the mixture was left standing for one hour.
Upon completion of the reaction, the reaction mixture was concentrated in vacuo, added with 7 l. of water, then extracted with one litre" of benzene.
The water layer is diluted to 50 1., and applied to an anion exchange resin Duolite A101D (Cl type, 101.) column. Cytidine-5'-diphosphate was eluted from the column with 0.1 N hydrochloride, and crystallized as trisodium salt (387 grammes (g.) (11.0 percent moisture)). Yield 73.5 percent.
Molar ratio of the components is indicated in Table 2:
Example 2.Trisodium inosine-5'-triphosphate (ITP Na To 200 millimoles of mono (tri-n-butylammoniurn) 5'-inosinate, 120 ml. of N,N-dimethyl acetamide and mixture of 250 millimoles of tetraphenylpyrophosphate, 100 ml. of tri-n-butylamine, and 600 ml. of dioxane were added successively.
After agitating 200 ml. of pyridine containing 400 millimoles of di (tri-n-butylammonium) pyrophosphate was then added to the batch.
The mixture was then left standing for 40 minutes synthesized inosine 5'-triphosphate was isolated from the reaction mixture by means of anion-exchange resin Duolite A101D (Cl type, 10 litres) column chromatography, and obtained amorphous powder as trisodium salt. (107.9 g. (10.3 percent moisture content)) Yield, 84.3 percent.
Molar ratio of the components is indicated in Table 3.
TABLE 3 Molar ratio Inosine Total P tfifiiiiiitifiifisiijiji i133 3135 Example 3.-Trisodium thymidine-5'-triphosphate (TTP Na To 10 millimoles of mono (tri-n-butylammonium)-5'- thymidylate, 5 ml. of N,N-dimethylformamide and mixture of 2.3 ml. of diphenylphosphorochloridate, 5 ml. of tri-n-butylamine, and 20 ml. of dioxane were added successively, after agitating ml. of pyridine containing 20 millimoles of di (tri-n-butylammonium) pyrophosphate was added to the batch. Then, after 30 minutes, thymidine-5-triphosphate was isolated from the reaction mixture as usual. The yield was 79.7 percent.
Example 4.-Disodium uridine-5'-diphosphoglucose (UDPG Na l0 millimoles of mono (tri-n-butylammonium) 5-uridylate was dissolved in 5 ml. of N,N-dimethylformamine, and 5 m1. of dioxane, 6 ml. of tri-n-butylamine, and 2.3 ml. of diphenyl phosphorochloridate were added to the resulting solution.
After 10 minutes 15 ml. of pyridine containing 12 millimoles of mono (tri-n-butylamr nonium) glucose-l-phosphate was added to the mixture.
After allowing to stand for two hours, the solvent was removed under reduced pressure.
The remaining substances were dissolved in water and applied to anion exchange resin Dowex 1 X8 (Cl column (100 ml.). Uridine-5-diphosphoglucose was eluted from the column as usual, and obtained amorphous powder as disodium salt (4.12 g.). Yield, 67.5 percent.
Molar ratio of the components is indicated in Table 4.
In addition 98.6 percent of the preparation was dehydrogenized by the action of UDPG dehydrogenase.
Example 5 .Adenosine-5-diphosphoglucose (ADPG) To one millimole of mono (methyl-tri-n-butylammonium) 5'-adenylate, 1 ml. of N,N-dimethy1 acetamide, 0.22 ml., of dephenyl phosphorochloridate 1 ml. of dioxane, and 0.5 ml. of tri-n-butylamine were added successively.
After 30 minutes, 3 ml. of pyridine containing 1.5 millimoles of mono (tri-n-butylammoniurn) glucose-l-phosphate was added to the mixture. During one hour reaction, adenosine-5'-diphosphoglucose was synthesized in a yield of 81.5 percent.
Example 6.Flavine-adenine-dinucleotide (FAD) One millimole of mono (tri-n-octylammonium) 5'- adenylate was dissolved in 1 ml. of N,N-dimethyl acetamide, and to the resulting solution, 0.25 ml. of diphenyl phosphorochloridate 2 ml. of dioxane, and 0.5 ml. of trin-butylamine were added.
Then 2 ml. of formamide containing 1.8 millimoles of a mono (methyl-tri-n-butylammonium) salt of flavine mononucleotide and 4 ml. of pyridine was added to the mixture. During 1.5 hours reaction, flavine-adenine-dinucleotide was synthesized in a yield of 78.3 percent.
Example 7.CDP-ethanolamine Two millimoles of mono (methyl tri n octylammonium) 5-cytidylate was dissolved in 2 ml. of N,N-dirnethyl formamide, and to resulting solution, 0.5 ml. of diphenyl phosphorochloridate, 1 ml. of tri-n-butylamine, and 15 ml. of dioxane were added, the resulting solution and then being mixed.
5 ml. of pyridine containing 3 millimoles of mono (methyl-tri-n-butylammonium) salt of o-phosphoethanolamine was then added to the mixture. During 30 minutes raction, CDP ethanolamine, was synthesized in a yield of 52.7 percent.
Example 8.-Uridylyl sulfate 10 millimoles of mono (tri-n-octylammonium) 5'-uridylate was dissolved in 20 ml. of dioxane, and to the resulting solution, 2.5 ml. of diphenyl phosphorochloridate and 2.1 ml. of triethylamine were added.
After the resulting batch was left standing for 5 minutes at room temperature, 20 millimoles of tri-n-butylammonium sulfate and 5 ml. of pyridine were added to the mixture.
During one hours reaction uridylyl sulfate was synthe sized in a yield of 40 percent.
Example 9.-Adenosine-5'-2,4-dinitrophenyl-phosphate To 1 millimole of mono (methyl-tri-n-butylarnmonium) 5'-adenylate, 2 ml. of N,N-dimethyl acetamide was added, and then 0.25 ml. of diphenyl phosphorochloridate and 0.6 ml. of tri-n-butylamine were added after allowing it to stand at room temperature for one hour, 2 ml. of pyridine containing a solution of 2 millimoles of 2,4- dinitrophenol was added to the mixture. During 2 hours reaction at C., adenosine-S'-2,4-dinitrophenol phosphate synthesized in a yield of 91 percent.
Example 10.Adenyl-'-yl-carbobenzyl oxyglycine To 1 millimole of mono (tri-n-octylammonium) 5- adenylate, 2 m1. of N,N-dimethy1 acetamide was added, after. agitation a mixture of 0.25 ml. of diphenyl phosphorochloridate, 4 ml. of dioxane, and 0.5 ml. of tri-nbutylamine were added to the solution, which was then thoroughly agitated for dissolution.
2 ml. of pyridine containing 250 mg. of carbobenzyloxyglycine was then added to the reaction mixture. During 3 hours reaction, adenyl-5'-yl-carbobenzyl oxyglycine was synthesized in a yield of 32 percent.
What is claimed is:
1. A one-stage process for producing a nucleotide anhydride which comprises adding a member selected from the group consisting of diphenyl phosphorochloridate and tetraphenyl pyrophosphate to an alkylammonium salt of a nucleoside-S'-monophosphate in a reaction solvent selected from the group consisting of dioxane, dimethylformamide, and dimethylacetamide and in the presence of an alkylamine and adding to the resulting mixture an alkylammonium salt of an acid dissolved in pyridine or one of its derivatives whereby said anhydride is produced in a single stage without isolation of an intermediate.
2. A process for producing a nucleotide anhydride anhydride as claimed in claim 1 in which the quantities of the principal substances used therein in terms of multiples of the quantity in moles of said nucleoside-5-monophosphate are to 50 times of said dioxane, dimethylformamide or dimethylacetamide, l to 1.5 times of said diphenyl phosphorochloridate, 2 to 10 times of said acid, and 5 to 30 times of said pyridine solvent, and the process is carried out at a reaction temperature of from 0 to 30 C.
3. A process for producing nucleotide anhydride as claimed in claim 2 in which:
said alkyl-ammonium salt of a nucleoside-S'-monophosphate is selected from mono (methyl-tri-n-butylammonium)-5'- cytidylate,
mono (tri-n-butylammonium)5'-inosinate,
mono (tri-n-butylammonium) -5 -thymidylate,
mono (tri-n-butylammonium) -5 '-uridylate,
mono (methyl-tri-n-butylammonium) -5 adenylate,
mono (tri-n-octylammonium -5 '-adenylate,
mono methyktri-n-octylammonium) -5 cytidylate,
mono tri-n-octylammonium -5 -uridylate,
mono methyl-tri-n-butylammonium -5 adenylate, and
mono (tri-n-octyla'mmonium -5-adenylate;
and said alkyl-ammonium salt of an acid is selected from I mono (tri-n-butylammonium) phosphate,
di(tri-n-butylammonium)pyrophosphate,
mono (tri-n-butylammonium) glucose- 1- phosphate,
mono(methyl-tri-n-butylamrnonium)salt of flavine mononucleotide,
mono(methyl-tri-n-butylammonium)salt of flavine mononucleotide,
mono (methyl-tri-n-butylammonium) salt of o-phosphoethanolamine,
tri-n-butylammonium sulfate,
2,4-dinitrophenol, and
carbobenzyloxyglycine,
to produce, respectively, one of the compounds selected from trisodium cytidine-5'-diphosphate (CD'P Na trisodium inosine-5'-triphosphate (ITP Na trisodium thymidine-S'-triphosphate (TIP Na disodium uridine 5' diphosphoglucose (UDPG N32), adenosine-5'-diphosphoglucose (ADPG), fiavine-adenine-dinucleotide (FAD), CDP-ethanolamine, uridylyl sulfate, adenosine-S'-2,4-dinitrophenylphosphate, and adenyl- '-yl-carbobenzyl oxyglycine.
4. In a process for the preparation of a nucleotide anhydride by the steps of reacting a nucleoside-5-monophosphate with a reagent selected from a member of the group consisting of tetraphenyl pyrophosphate and diphenyl phosphorochloridate in the presence of a tertiary base and in a solvent, isolating and purifying the resultant P -nucleoside-5'-P -dipheny1 pyrophosphate, and then reacting said P -nucleoside-5'-P -diphenyl pyrophosphate with an acid having a weaker acidity than diphenyl phosphate to produce said anhydride, the improvement which comprises carrying out said preparation in a single stage without isolation and purification of said P -nucleoside- 5'-P -diphenyl pyrophosphate by mixing an alkylammonium salt of said nucleoside-5'-monophosphate with said reagent in a solvent which does not inhibit the reaction in the presence of an alkylamine and then adding directly to the resultant mixture an alkylammonium salt of said acid dissolved in pyridine or a pyridine derivative to form said anhydride.
References Cited UNITED STATES PATENTS 3,089,869 5/1963 Mauvernay 260--21l.5 R 3,299,043 1/ 1967 Schramm et al. 26021l.5 R 3,321,146 5/1967 Moifatt 260-2115 R 3,321,463 5/ 1967 Moflatt 260211.5 R
LEWIS GOTTS, Primary Examiner J. R. BROWN, Assistant Examiner US. Cl. X.R. 260-9'99
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP44045786A JPS4910674B1 (en) | 1969-06-12 | 1969-06-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3701772A true US3701772A (en) | 1972-10-31 |
Family
ID=12728948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US42579A Expired - Lifetime US3701772A (en) | 1969-06-12 | 1970-06-01 | Production of nucleotide anhydrides |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US3701772A (en) |
| JP (1) | JPS4910674B1 (en) |
| CA (1) | CA931141A (en) |
| FR (1) | FR2051064A5 (en) |
| GB (1) | GB1316772A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3893998A (en) * | 1973-02-22 | 1975-07-08 | Univ Illinois | Fluorescent derivatives of cytosine-containing compounds |
| US3960840A (en) * | 1972-12-29 | 1976-06-01 | University Of Illinois Foundaton | Fluorescent derivatives of adenine-containing compounds |
| US4816570A (en) * | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US5401725A (en) * | 1990-11-08 | 1995-03-28 | Unitika Ltd. | Neovascularization inhibition by adenosine-5'-phosphosulfates |
| US6303774B1 (en) * | 1999-08-20 | 2001-10-16 | Sri International | Nucleoside pyrophosphate and triphosphate analogs and related compounds |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5159067A (en) * | 1987-01-28 | 1992-10-27 | University Of Georgia Research Foundation Inc. | 5'-Diphosphohexose nucleoside pharmaceutical compositions |
| US5118672A (en) * | 1989-07-10 | 1992-06-02 | University Of Georgia Research Foundation | 5'-diphosphohexose nucleoside pharmaceutical compositions |
-
1969
- 1969-06-12 JP JP44045786A patent/JPS4910674B1/ja active Pending
-
1970
- 1970-06-01 US US42579A patent/US3701772A/en not_active Expired - Lifetime
- 1970-06-03 CA CA084563A patent/CA931141A/en not_active Expired
- 1970-06-10 GB GB2817270A patent/GB1316772A/en not_active Expired
- 1970-06-11 FR FR7021422A patent/FR2051064A5/fr not_active Expired
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3960840A (en) * | 1972-12-29 | 1976-06-01 | University Of Illinois Foundaton | Fluorescent derivatives of adenine-containing compounds |
| US3893998A (en) * | 1973-02-22 | 1975-07-08 | Univ Illinois | Fluorescent derivatives of cytosine-containing compounds |
| US4816570A (en) * | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US5401725A (en) * | 1990-11-08 | 1995-03-28 | Unitika Ltd. | Neovascularization inhibition by adenosine-5'-phosphosulfates |
| US6303774B1 (en) * | 1999-08-20 | 2001-10-16 | Sri International | Nucleoside pyrophosphate and triphosphate analogs and related compounds |
| US6613926B1 (en) | 1999-08-20 | 2003-09-02 | Sri International | Perchloramido phosphonyl reagents and analogs thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2051064A5 (en) | 1971-04-02 |
| CA931141A (en) | 1973-07-31 |
| JPS4910674B1 (en) | 1974-03-12 |
| GB1316772A (en) | 1973-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0212536B1 (en) | 7-deaza-2'-deoxyguanosin-nucleotides, process for their preparation and their use in nucleic-acid sequencing | |
| Roseman et al. | Nucleoside polyphosphates. XI. 1 An improved general method for the synthesis of nucleotide coenzymes. Syntheses of uridine-5', cytidine-5'and guanosine-5'diphosphate derivatives | |
| Moffatt et al. | Nucleoside Polyphosphates. X. 1 The Synthesis and Some Reactions of Nucleoside-5'Phosphoromorpholidates and Related Compounds. Improved Methods for the Preparation of Nucleoside-5'Polyphosphates1 | |
| DE2122529C2 (en) | ||
| US3321463A (en) | Process for the preparation of nucleoside-5'-polyphosphates and alpha, omega-bis-(nucleoside-5') polyphosphates | |
| IKEHARA et al. | Studies of nucleosides and nucleotides. LXXXII. Cyclonucleosides.(39). Synthesis and Properties of 2'-halogeno-2'-deoxyadenosines | |
| US3642772A (en) | Process for preparing s-adenosyl homocysteine | |
| Ralph et al. | Studies on Polynucleotides. XVIII. 1 Experiments on the Polymerization of Mononucleotides. The Synthesis and Characterization of Deoxyguanosine Oligonucleotides 2 | |
| Robins et al. | The synthesis of 2′, 3′-dideoxyadenosine from 2′-deoxyadenosine | |
| Chambers et al. | Nucleoside Polyphosphates. VII. 1 The Use of Phosphoramidic Acids in the Synthesis of Nucleoside-5'Pyrophosphates | |
| DE2628202A1 (en) | PROCESS FOR THE PREPARATION OF 2'-SUBSTITUTE-D-RIBOFURANOSYLPURINE DERIVATIVES | |
| US3701772A (en) | Production of nucleotide anhydrides | |
| US2844514A (en) | Process for the production of nucleotides | |
| Kozarich et al. | Ribonucleoside phosphates via phosphorimidazolidate intermediates. Synthesis of pseudoadenosine 5'-triphosphate | |
| DE1695303A1 (en) | Process for the preparation of nucleoside 5'-diphosphates and triphosphates as well as mono- and oligonucleotidyl nucleside-5'-diphosphates and triphosphates | |
| US3709873A (en) | Process for synthesizing the di-esters of condensed phosphoric acid | |
| Imai et al. | Expedient chemical synthesis of sequence-specific 2', 5'-oligonucleotides | |
| Koch et al. | Radical Rearrangements of 2‐O‐(Diphenoxyphosphoryl) glycosyl Bromides | |
| US2970139A (en) | 5-fluorouracil nucleotides and preparation thereof | |
| US3201388A (en) | Method of preparing 5'-ribonucleotides | |
| US3803125A (en) | Process for making nucleoside diphosphate compounds | |
| US2795580A (en) | Synthesis of nucleoside polyphosphates | |
| US3755296A (en) | Process for preparing 1-{62 -d-arabinofuranosyl-cytosine and 2,2{40 -cyclocytidine | |
| US3079379A (en) | Method for the preparation of adenosine 5'-triphosphate | |
| MacDonald | Preparation of glycosyl phosphates. β-D-fructopyranose 2-phosphate |